Investigating how TLE1 affects the aggressiveness of lung adenocarcinoma
Role of the transcriptional corepressor TLE1 in the lung adenocarcinoma aggressiveness and progression
This study is looking at a protein called TLE1 to see how it helps lung adenocarcinoma cells survive and grow, even when they usually shouldn't, with the hope of finding new ways to treat this tough type of lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xavier University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11081675 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called TLE1 in lung adenocarcinoma, a type of lung cancer known for its aggressive nature. The study aims to explore how TLE1 contributes to cancer cell survival and growth, particularly in conditions that typically lead to cell death. By examining the molecular mechanisms involved, including the interaction with other genes and proteins, the research seeks to identify potential targets for new cancer therapies. Patients may benefit from insights gained that could lead to improved treatment strategies for lung adenocarcinoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with lung adenocarcinoma, particularly those with aggressive forms of the disease.
Not a fit: Patients with other types of lung cancer or those without a diagnosis of lung adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that improve survival rates for patients with lung adenocarcinoma.
How similar studies have performed: Previous research has shown promising results in targeting similar molecular pathways in cancer treatment, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
New Orleans, United States
- Xavier University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Biliran, Hector Ramos — Xavier University of Louisiana
- Study coordinator: Biliran, Hector Ramos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.